Artículo
Acceso Abierto

Metformin Reverts Deleterious Effects of Advanced Glycation End-Products (AGEs) on Osteoblastic Cells

Enlace externo
Resumen

Advanced glycation endproducts (AGEs) are implicated in the complications of diabetes and ageing, affecting several tissues, including bone. Metformin, an insulin-sensitizer drug, reduces the risk of life-threatening macrovascular complications. We have evaluated the hypothesis that metformin can abrogate AGE-induced deleterious effects in osteoblastic cells in culture. In two osteoblast-like cell lines (UMR106 and MC3T3E1), AGE-modifi ed albumin induced cell death, caspase- 3 activity, altered intracellular oxidative stress and inhibited alkaline phosphatase activity. Metformin-treatment of osteoblastic cells prevented these AGE-induced alterations. We also assessed the expression of AGE receptors as a possible mechanism by which metformin could modulate the action of AGEs. AGEs-treatment of osteoblast-like cells enhanced RAGE protein expression, and this up-regulation was prevented in the presence of metformin. Although the precise mechanisms involved in metformin signaling are still elusive, our data implicate the AGE-RAGE interaction in the modulation of growth and differentiation of osteoblastic cells.

Palabras clave
Metformin
Advanced glycation end product
Osteoblasts
Oxidative stress
RAGO
http://creativecommons.org/licenses/by-nc-sa/4.0/

Esta obra se publica con la licencia Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (BY-NC-SA 4.0)

item.page.license
Cargando...
Miniatura